EUCTR2004-000501-21-GB进行中（未招募）1 期
A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-B, a Mixture of Two Monoclonal Antibodies, as Compared to Hepatitis B Immune Globulin in Patients who have Received Hepatic Allografts for Treatment of End-Stage Liver Disease due to Hepatitis B Virus Infection
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male and female patients who are 18 years of age or older,
- •2. Patients who are at least 6 months post first orthotopic liver transplantation (living or cadaveric donor) for treatment of end-stage liver disease due to hepatitis B virus infection,
- •3. Patients who have received HBIg since transplantation and are on a stable regimen (i.e., same dose and frequency) for at least the 3 months immediately preceding study entry (Day 1).
- •4. Patients who have received treatment with an inhibitor of HBV polymerase for at least the 3 months immediately preceding study entry (Day 1)
- •5. Patients with undetectable HBsAg and HBV DNA concentrations on two consecutive tests at least one week apart during the screening period,
- •6. Female patients who are of childbearing potential, and males whose partners are women of childbearing potential, are required to use adequate contraception, and
- •7. Patients who are able to provide written informed consent.
- •8. Patients who successfully complete the initial 20-week treatment in the core trial are eligible for the 52-week extension phase.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Women who are pregnant or breastfeeding,
- •2. Patients who have received another organ transplant that requires immunosuppression,
- •3. Patients who are co-infected with hepatitis delta virus (HDV), hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV),
- •4. Patients with clinical conditions or diseases, which, in the judgment of the investigator, would place the patient at undue risk, interfere with study participation, or confound the results of the study, and/or
- •5. Patients who have participated in clinical studies in the 3 months prior to study entry.
研究者
相似试验
进行中（未招募）
1 期
1L NSCLC Phase II RCT M7824 vs Pembrolizumabon-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001517-32-ITMERCK KGAA300
进行中（未招募）
1 期
1L NSCLC Phase II RCT M7824 vs PembrolizumabEUCTR2018-001517-32-GRMerck KGaA300
进行中（未招募）
1 期
1L NSCLC Phase II RCT M7824 vs Pembrolizumabon-small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001517-32-ESMerck KGaA300
招募中
1 期
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerCTIS2023-504027-78-00F. Hoffmann-La Roche AG244
进行中（未招募）
1 期
Study to investigate the function of three medicinal products (monoclonal antibodies) on a population of patients with colorectal cancer that has spread from its site of origin to another part of the body.Metastatic Colorectal CarcinomaEUCTR2018-000618-39-ESSymphogen A/S54